|
Name |
(1R,4S,5R)-1,8-Dimethyl-4-(prop-1-en-2-yl)spiro[4.5]dec-7-ene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(1R,4S,5R)-1,8-dimethyl-4-prop-1-en-2-ylspiro[4.5]dec-8-ene
|
|
SMILES |
C[C@@H]1CC[C@H]([C@@]12CCC(=CC2)C)C(=C)C
|
|
InChI |
InChI=1S/C15H24/c1-11(2)14-6-5-13(4)15(14)9-7-12(3)8-10-15/h7,13-14H,1,5-6,8-10H2,2-4H3/t13-,14+,15+/m1/s1
|
|
InChIKey |
DVBSKQAFCDJNSL-ILXRZTDVSA-N
|
|
Synonyms |
28477-64-7; beta-Acoradiene; (1R,4S,5R)-1,8-Dimethyl-4-(prop-1-en-2-yl)spiro[4.5]dec-7-ene; (1R,4S,5R)-1,8-dimethyl-4-(1-methylethenyl)spiro[4.5]dec-7-ene; .beta.-Acoradiene; (-)-beta- acoradiene; Acoradiene, (-)-beta-; DTXSID90601964; CHEBI:172925
|
|
CAS | 28477-64-7 | |
PubChem CID | 20055537 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 5.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.518 |
Caco-2 Permeability: | -4.424 | MDCK Permeability: | 0.00001590 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.947 |
30% Bioavailability (F30%): | 0.297 |
Blood-Brain-Barrier Penetration (BBB): | 0.295 | Plasma Protein Binding (PPB): | 95.24% |
Volume Distribution (VD): | 4.409 | Fu: | 4.84% |
CYP1A2-inhibitor: | 0.855 | CYP1A2-substrate: | 0.27 |
CYP2C19-inhibitor: | 0.515 | CYP2C19-substrate: | 0.847 |
CYP2C9-inhibitor: | 0.292 | CYP2C9-substrate: | 0.573 |
CYP2D6-inhibitor: | 0.071 | CYP2D6-substrate: | 0.522 |
CYP3A4-inhibitor: | 0.711 | CYP3A4-substrate: | 0.253 |
Clearance (CL): | 10.557 | Half-life (T1/2): | 0.108 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.314 |
Drug-inuced Liver Injury (DILI): | 0.096 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.021 | Maximum Recommended Daily Dose: | 0.735 |
Skin Sensitization: | 0.882 | Carcinogencity: | 0.287 |
Eye Corrosion: | 0.963 | Eye Irritation: | 0.981 |
Respiratory Toxicity: | 0.159 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000786 | 1.000 | D04SFH | 0.253 | ||||
ENC002990 | 0.519 | D0F1UL | 0.250 | ||||
ENC003255 | 0.519 | D0B4RU | 0.250 | ||||
ENC001813 | 0.464 | D07BSQ | 0.250 | ||||
ENC001832 | 0.414 | D04GJN | 0.225 | ||||
ENC001924 | 0.414 | D0I2SD | 0.225 | ||||
ENC005089 | 0.410 | D02CJX | 0.221 | ||||
ENC001831 | 0.390 | D02CNR | 0.216 | ||||
ENC002110 | 0.390 | D0A2AJ | 0.213 | ||||
ENC001437 | 0.390 | D0V2JK | 0.211 |